TAMPA, FLORIDA / ACCESS Newswire / August 14, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) (“Wellgistics Health” or the “Company”), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the termination of its equity purchase agreement (“ELOC”) with Hudson Global Ventures, LLC.
The ELOC was an effective tool that nearly doubled the Company’s original IPO raise. The decision to terminate the agreement reflects a strategic shift toward accretive financing and reinforces its aim of long-term shareholder value creation.
Management cited strong execution in expanding its independent pharmacy network, accelerating adoption of its AI-powered prescription routing technology and payment platforms, and creating a strong pipeline for growth opportunities with manufacturer direct-to-patient (DTP) platforms as drivers behind the move. This unique approach is designed to bypass traditional PBM barriers, increase manufacturer margins, and accelerate patient access.
“From a financial standpoint, terminating the ELOC aligns with our disciplined approach to capital structure and shareholder equity preservation,” said Mark DiSiena, Chief Financial Officer of Wellgistics Health. “It allows us to secure more favorable funding opportunities so we can focus on our strategic plans, optimize our cost of capital, and pursue options that better reflect our growth trajectory.”
“This decision reflects the discipline we’re bringing to every part of the business,” said Brian Norton, Chief Executive Officer of Wellgistics Health. “We’ve moved past the challenges of our opening quarters and are entering a new chapter built on operational strength and strategic execution. We’re ready to show the market what we’re truly capable of – delivering smarter, faster access to medicine, empowering independent pharmacies, and creating lasting value across the healthcare ecosystem.”
About Wellgistics Health
Wellgistics Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ independent pharmacies and 200+ U.S. manufacturers, providing wholesale distribution, digital prescription routing, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics Health offers compliant, end-to-end solutions that restore access, transparency, and trust in U.S. healthcare.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from Wellgistics Health’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, market conditions and other risks detailed in our reports and statements filed with the SEC. Investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.
Skyline Corporate Communications Group, LLC Scott Powell, President 1177 Avenue of the Americas, 5th Floor New York, NY 10036 Office: (646) 893-5835 Email: info@skylineccg.com
Company Reports Quarterly Revenue of $1.2 Million; Net Loss and Loss per Diluted Share of $2.2 Million and $2.13
Quarterly Adjusted EBITDA Loss of $1.7 Million Reflects 40% YOY Improvement
TRNR held 29.6 Million FET tokens as of June 30, 2025 and 67.4 Million FET tokens as of August 13, 2025, with a value in excess of $50 million, representing the largest publicly traded AI-focused Digital Asset Treasury
Stockholders’ Equity Was $16.3 Million at Quarter End
2025 Pro Forma Revenue Guidance Increased to more than $80 Million, driven by Sportstech’s Stronger-Than-Expected Performance, and Fourth Quarter Profitability Guidance Reiterated
AUSTIN, TEXAS / ACCESS Newswire / August 14, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) (“TRNR” or the “Company”), maker of innovative specialty fitness equipment under the Wattbike, CLMBR and FORME brands, and the pending acquirer of Sportstech, today announced financial results for its second quarter ended June 30, 2025.
Quarterly Financial Highlights
For the quarter, TRNR reported revenue of $1.2 million, a net loss of $2.2 million – or $2.13 per diluted share – and an Adjusted EBITDA loss of approximately $1.7 million (non‑GAAP).
Results do not include Wattbike (closed July 1, 2025) or Sportstech (pending) for the period. However, if both businesses were included in the second quarter, revenue would have been approximately $17 million.
Digital Asset Treasury Strategy
TRNR also closed a very significant investment in the quarter to begin to execute its Digital Asset Treasury Strategy, and was able to acquire 29.6 million FET tokens by the end of the Q2. TRNR has since completed the cumulative purchase of 67.4 million FET tokens, at an average token price of $0.70, currently worth in excess of $50 million.
Outlook
TRNR is increasing its full‑year 2025 pro forma revenue guidance to more than $80 million, driven by Sportstech’s stronger-than-expected-performance, and by continued momentum across the TRNR + Wattbike platform. TRNR is also reiterating its guidance that it expects to achieve Adjusted EBITDA profitability in the fourth quarter.
Sportstech
The Sportstech acquisition continues to proceed and all parties are working to satisfy the remaining items to close the acquisition and look forward to being able to update investors with more specific guidance on the transaction as soon as possible.
Founder and CEO Trend Ward stated: “We believe that Q2 will be the inflection point for TRNR, as we now have the largest publicly traded AI-focused Digital Asset Treasury, comprised of 67.4 million FET tokens, worth more than $50 million, and we are increasing our 2025 pro forma revenue guidance to more than $80 million, driven by the stronger-than-expected performance of Sportstech, our pending acquisition. We closed the Wattbike acquisition right after the quarter had ended and all parties are working on completing the remaining items to close the Sportstech acquisition as soon as we can. If both acquisitions were included in the second quarter, we would have generated approximately $17 million in revenue for the quarter. We are also reiterating that we expect to be profitable in the fourth quarter. In our view, the combination of these synergistic acquisitions, along with our AI-focused Digital Asset Treasury, represents a significant opportunity for investors.”
For more commentary, information and details of TRNR’s strategy, as well as to sign up for direct updates, see the Company’s investor website, latest FAQs and required filings with the US Securities & Exchange Commission (SEC).
Interactive Strength Inc. (NASDAQ:TRNR) has established a leading portfolio of premium fitness brands-Wattbike, CLMBR, and FORME-that combine advanced hardware, smart technology, and immersive content to deliver exceptional training experiences for both commercial and home use.
Wattbike offers a range of high-performance indoor bikes that set the global standard in cycling. Known for unmatched accuracy, realistic ride feel, and advanced performance tracking, Wattbike is trusted by elite athletes, national teams, and fitness enthusiasts around the world.
CLMBR redefines the next-generation vertical climbing experience through its patented open-frame design and immersive touchscreen, delivering a high-intensity, low-impact workout that’s both efficient and effective.
FORME delivers strength, mobility, and recovery training through immersive content, performance-grade hardware, and expert coaching. Its wall-mounted systems include the Studio, a smart fitness mirror for guided programming and live 1:1 personal training, and the Lift, which adds smart resistance cable training-ideal for high-performance environments and sport-specific development.
From elite performance to everyday wellness, our ecosystem of performance-focused solutions delivers data-driven outcomes for athletes, fitness enthusiasts, and commercial operators.
Channels for Disclosure of Information In compliance with disclosure obligations under Regulation FD, we announce material information to the public through a variety of means, including filings with the Securities and Exchange Commission (“SEC”), press releases, company blog posts, public conference calls, and webcasts, as well as via our investor relations website. Any updates to the list of disclosure channels through which we may announce information will be posted on the investor relations page on our website. The inclusion of our website address or the address of any third-party sites in this press release are intended as inactive textual references only.
Non-GAAP Financial Measures In addition to our results determined in accordance with accounting principles generally accepted in the United States, or GAAP, we believe the following non-GAAP financial measures are useful in evaluating our operating performance.
The Company’s non-GAAP financial measure in this press release consist of Adjusted EBITDA, which we define as net (loss) income, adjusted to exclude: other expense (income), net; income tax expense (benefit); depreciation and amortization expense; stock-based compensation expense; (gain) loss on debt extinguishment; vendor settlements; and transaction related expenses.
The Company believes the above adjusted financial measures help facilitate analysis of operating performance and the operating leverage in our business. We believe that these non-GAAP financial measures are useful to investors for period-to-period comparisons of our business and in understanding and evaluating our operating results for the following reasons:
Adjusted EBITDA is widely used by investors and securities analysts to measure a company’s operating performance without regard to items such as stock-based compensation expense, depreciation and amortization expense, other expense (income), net, and provision for income taxes that can vary substantially from company to company depending upon their financing, capital structures, and the method by which assets were acquired;
Our management uses Adjusted EBITDA in conjunction with financial measures prepared in accordance with GAAP for planning purposes, including the preparation of our annual operating budget, as a measure of our core operating results and the effectiveness of our business strategy, and in evaluating our financial performance; and
Adjusted EBITDA provides consistency and comparability with our past financial performance, facilitate period-to-period comparisons of our core operating results, and may also facilitate comparisons with other peer companies, many of which use similar non-GAAP financial measures to supplement their GAAP results.
Our use of Adjusted EBITDA, or any other non-GAAP financial measures we may use in the future, is presented for supplemental informational purposes only and should not be considered as a substitute for, or in isolation from, our financial results presented in accordance with GAAP. Further, these non-GAAP financial measures have limitations as analytical tools. Some of these limitations are, or may in the future be, as follows:
Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;
Adjusted EBITDA excludes stock-based compensation expense, which has recently been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy;
Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) interest expense, or the cash requirements necessary to service interest or principal payments on our debt, which reduces cash available to us; or (3) tax payments that may represent a reduction in cash available to us;
Adjusted EBITDA does not reflect impairment charges for fixed assets and capitalized content, and gains (losses) on disposals for fixed assets;
Adjusted EBITDA does not reflect (gains) losses associated with debt extinguishments.
Adjusted EBITDA does not reflect losses associated with vendor settlements.
Adjusted EBITDA does not reflect transaction related expenses for CLMBR acquisition and pending acquisitions of Wattbike and Sportstech.
Adjusted EBITDA does not reflect non cash fair value gains (losses) on convertible notes, derivatives, warrants and unrealized currency gains (losses).
Further, the non-GAAP financial measures presented may not be comparable to similarly titled measures reported by other companies due to differences in the way that these measures are calculated. For example, the expenses and other items that we exclude in our calculation of Adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from Adjusted EBITDA when they report their operating results. Because companies in our industry may calculate such measures differently than we do, their usefulness as comparative measures is limited. Because of these limitations, Adjusted EBITDA should be considered along with other operating and financial performance measures presented in accordance with GAAP.
Forward Looking Statements:
This press release includes certain statements that are “forward-looking statements” for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements generally are accompanied by words such as “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan”, “may”, “should”, “will”, “would”, “will be”, “will continue”, “will likely result” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the value or potential opportunity of the digital asset treasury strategy, its value staying above $50 million, the possibility of acquiring future businesses or completing the referenced pending transactions in a timely manner or at all, the financial performance of those acquisitions and the resulting guidance of having more than $80m of pro forma revenue in 2025, achieving profitability by Q4, and the financial performance of the acquisition targets which have not been audited or reviewed by a PCAOB auditor and could vary materially (a) once that audit or review work is completed and such financials are included in the Company’s reported financials and (b) due to the effect of the exchange rates of foreign currencies which can be volatile, or that the business is at an inflection point in Q2 and that there is a significant opportunity for investors. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Risks and uncertainties include but are not limited to: demand for our products and the products of the acquisition targets if the acquisitions are completed (collectively, the “Products”); competition, including technological advances made by and new products released by our competitors and the competitors of the acquisition targets; our ability to accurately forecast consumer demand for our Products and adequately maintain our inventory; and our reliance on a limited number of suppliers and distributors for our Products. A further list and descriptions of these risks, uncertainties and other factors can be found in filings with the Securities and Exchange Commission. To the extent permitted under applicable law, the Company assumes no obligation to update any forward-looking statements.
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 million
Mytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2 2025 was equal to the volume in Q2 2024
As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar’s orphan indication products, resulting in non-dilutive funding for Jaguar
REMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q2 2025 financials and company updates; Click here to register
SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today reported its consolidated second-quarter 2025 financial results.
2025 SECOND QUARTER COMPANY FINANCIAL RESULTS:
Net Prescription Products Revenue: The combined net revenue for the Company’s prescription products (Mytesi®, Gelclair®, and Canalevia®-CA1) was approximately $2.9 million in the second quarter of 2025, representing an increase of approximately 36% over the combined net revenue in the first quarter of 2025, which totaled approximately $2.2 million, and an increase of approximately 10% over the combined net revenue for the second quarter of 2024, which totaled approximately $2.7 million.
Mytesi Prescription Volume: Mytesi prescription volume increased by approximately 6.5% in the second quarter of 2025 over the first quarter of 2025, and Mytesi prescription volume in the second quarter of 2025 was equal to the volume in the second quarter of 2024. Prescription volume differs from invoiced sales volume, which reflects, among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels.
License Revenue: For the second quarter of 2025, the Company recognized license fees of $42,500 from a securities purchase agreement with a European partner. As of June 30, 2025, the total deferred revenue associated with this contract amounts to approximately $637,500.
Neonorm™: Revenues for the non-prescription Neonorm products were minimal for the second quarters of 2025 and 2024.
Three Months Ending
Financial Highlights
June 30,
(in thousands, except per share amounts)
2025
2024
$ change
% change
Net product revenue
$
2,979
$
2,721
258
9
%
Loss from operations
$
(8,007
)
$
(7,197
)
(810
)
11
%
Net loss attributable to common stockholders
$
(10,406
)
$
(9,492
)
(914
)
10
%
Net loss per share, basic and diluted
$
(10.25
)
$
(2.66
)
(8
)
285
%
Cost of Product Revenue: Total cost of product revenue increased by approximately $0.1 million, from $0.4 million for the quarter ended June 30, 2024 compared to $0.5 million for the quarter ended June 30, 2025, due to increased sales of Mytesi.
Research and Development: The R&D expense decreased by $0.4 million, from $3.7 million for the quarter ended June 30, 2024 compared to $3.3 million for the quarter ended June 30, 2025, primarily due to the conclusion of the Phase 3 OnTarget clinical trial, which reduced trial-related contract manufacturing services and regulatory activities.
Sales and Marketing: The Sales and Marketing expense increased by approximately $1.0 million, from $1.5 million for the quarter ended June 30, 2024 to $2.5 million during the same quarter in 2025. The increase in expense was mostly due to headcount and promotional activities related to commercialization of Gelclair, which began in the end of 2024.
General and Administrative: The G&A expense increased by approximately $0.4 million, from $4.3 million for the quarter ended June 30, 2024 to $4.7 million during the same quarter in 2025, largely due to increased legal and compliance expenses.
Loss from Operations: Loss from operations increased by $0.8 million, from $7.2 million in the quarter ended June 30, 2024 to $8.0 million during the same period in 2025.
Net Loss: Net loss attributable to common shareholders increased by approximately $1.0 million, from $9.46 million in the quarter ended June 30, 2024 to $10.46 million in the same period in 2025. In addition to the loss from operations:
Interest expense decreased by $93,000, from $108,000 for the quarter ended June 30, 2024 to approximately $15,000 income in the same period in 2025, primarily due to changing the accounting of certain debt instruments designated at Fair Value Option (FVO).
The fair value of financial and hybrid instrument designation at FVO decreased by $0.7 million, from a loss of $1.8 million in the three months ended June 30, 2024, to a loss of $1.1 million in the same period in 2025, primarily due to fair value adjustments in liability classified warrants and notes payable designated at FVO.
Non-GAAP Recurring EBITDA: Non-GAAP recurring EBITDA for the second quarters of 2025 and 2024 were a net loss of $7.9 million and $8.8 million, respectively.
Three Months Ending
June 30,
(in thousands)
2025
2024
$ change
% change
(unaudited)
Net loss attributable to common stockholders
$
(10,406
)
$
(9,492
)
914
-10
%
Adjustments:
Interest income
(15
)
(108
)
(93
)
86
%
Property and equipment depreciation
16
17
1
4
%
Amortization of intangible assets
427
430
3
1
%
Share-based compensation expense
279
387
109
28
%
Loss on extinguishment of debt
1,822
–
(1,822
)
-100
%
Non-GAAP EBITDA
(7,877
)
(8,766
)
(888
)
10
%
Note Regarding Use of Non-GAAP Measures
The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.
The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar’s performance and provide useful information to investors regarding the Company’s results of operations and financial condition.
Participation Instructions for Webcast
When: Thursday, August 14, 2025 at 8:30 a.m. Eastern
Participant Registration & Access Link: Click Here
Replay Instructions for Webcast
Replay of the webcast on the investor relations section of Jaguar’s website: (click here)
About Crofelemer
Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
About Gelclair®
INDICATIONS
GELCLAIR® has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.
IMPORTANT SAFETY INFORMATION
Do not use GELCLAIR if there is a known or suspected hypersensitivity to any of its ingredients.
No adverse effects have been reported in clinical trials, although postmarketing reports have included infrequent complaints of burning sensation in the mouth.
If GELCLAIR is swallowed accidentally, no adverse effects are anticipated.
If no improvement is seen within 7 days, a physician should be consulted.
You are encouraged to report negative side effects of prescription medical products to the FDA.
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling.Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it will hold an investor webcast on August 14, 2025, and statements regarding Jaguar’s planned regulatory pathway to complete a supplemental NDA for crofelemer for patients with metastatic breast cancer. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
17 Total Broadcasts, Including Regular-Season and Preseason Games, will air on the stations in addition to streaming on Victory+
DALLAS, TX / ACCESS Newswire / August 14, 2025 / Victory+™ is excited to announce a new broadcast partnership with KDFW FOX 4 and KDFI More 27, bringing more Dallas Stars action to local TV viewers as the team builds from a spectacular 24/25 season. The arrangement will see a total of 17 Dallas Stars NHL games, including 15 regular-season games and 2 preseason matchups, airing across the local stations, giving Stars fans more ways to join in the action.
KDFW FOX 4 will air 9 games, and KDFI More 27 will air 8 games, with exact matchups and dates to be confirmed.
As Victory+ approaches its one– year anniversary, Texas sports fans have much to celebrate as, in addition to streaming Dallas Stars and Texas Rangers games, Victory+ recently announced the addition of Texas High School Football, including a game of the week and the State Championships for free.
“More access to more fans is at the core of what Victory+ offers, and we’re thrilled to expand our relationship with FOX 4 and KDFI to offer 17 Dallas Stars games to the local community,” said Neil Gruninger, President & CEO of APMC, parent company of Victory+. “This collaboration helps bring the excitement of Stars hockey into fans’ homes, and we’re proud to offer this as we continue to grow and engage with our audience.”
“Following the success of last season’s partnership with Victory+, we are pleased that this season we can provide local fans with the chance to see significantly more Stars action,” said Jeff Gurley, SVP and General Manager of KDFW FOX 4 and KDFI More 27. “This is a natural addition to our already strong coverage of the team, in an effort to serve the passionate Dallas hockey community who deserves it.”
“We’re excited to see the Stars’ continued success on Victory+ and to expand access for our fans in Dallas,” added Brad Alberts, President & CEO of the Dallas Stars. “Working with FOX 4 and KDFI gives our fans another platform to catch our games, and we’re thrilled to continue growing our audience together.”
This new deal reinforces the commitment to offering local viewers enhanced access to premium sports content as the Dallas Stars aim for a strong season and a deep playoff run.
ABOUT APMC and Victory+
A Parent Media Co. Inc. (APMC) is a media and technology company focused on providing innovative solutions to consumers and brands. APMC is a leader in Safe Streaming™ delivering an end-to-end solution to brands and platforms with an emphasis on unlocking incremental revenue. Utilizing proprietary streaming and monetization technologies, APMC reaches millions of homes globally through its products including Kidoodle.TV®, Dude Perfect Streaming Service, Glitch+™, Victory+™ and Safe Exchange™. Victory+ a groundbreaking FREE end-to-end, direct to consumer, sports streaming service made for fans, by fans. Featuring free regional broadcasts of various sports teams including the Dallas Stars, Anaheim Ducks, and Texas Rangers. Victory+ is also the home to a library of on-demand, premium sports-based, outdoors, and extreme sports content. Visit www.aparentmedia.com and www.victoryplus.com to learn more.
Comparable clinic revenues increase 5.7% vs prior year period
Net losses decrease 10% vs. prior year period
VIRGINIA BEACH, VA / ACCESS Newswire / August 14, 2025 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., today reported financial results for the second quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights Compared to Prior Periods
Total revenue of approximately $4.3 million, a sequential increase of 20% from Q1 2025 and a decrease of 2% from the prior year period. The decrease in revenue is attributed to the exclusion of the Hawaii clinic (KVC) from 2025 results
Services revenue of approximately $3.2 million, a sequential increase of 17% from Q1 2025 and a decrease of 1% from the prior year period
Product revenue of $1.1 million, a sequential increase of 21% from Q1 2025 and a decrease of 7% from the prior year period
Comparable clinic revenues increased 5.7% from the prior year period
Total operating expenses of $6.2 million, an increase of 5% from the prior year period
Net loss of $3.0 million, a decrease of $0.4 million from the prior year period
Entered an exclusive, non-binding Letter of Intent to acquire 100% ownership interest in one animal hospital located in New Jersey. Once completed, the acquisition could potentially add up to approximately $2.0 million in (unaudited) revenue
Entered into a securities purchase agreement for the issuance and sale of securities for up to $10M under a new convertible preferred stock transaction. The consideration, consisting of a combination of cash and transferred securities, was valued at $1.00 per share
Announced the launch of a company-wide incentive and recognition program, which provides vital new engagement tools and offers new avenues to wealth for all employees across their clinic network
Integrated a new artificial intelligence (AI) platform in partnership with leading software provider Covetrus into the Company’s medical software. The Company believes this is the only AI platform being offered among publicly traded veterinary clinic networks
Acquired 100% ownership interest in one animal hospital located in central Florida (DeBary). The acquisition is expected to add up to approximately $1.8 million in (unaudited) revenue, and brings the Company’s Florida holdings up to 5 clinics
For the second quarter of 2025, total revenue was approximately $4.3 million, a decrease of 2% from the prior year period but an increase of 20% from Q1 2025. Comparable clinic revenues increased 5.7% from the prior year period.
Second Quarter 2025 Operational Highlights
Entered an exclusive, non-binding Letter of Intent to acquire 100% ownership interest in one animal hospital located in New Jersey. Once completed, the acquisition could potentially add up to approximately $2.0 million in (unaudited) revenue
Entered into a securities purchase agreement for the issuance and sale of securities for up to $10M under a new convertible preferred stock transaction. The consideration, consisting of a combination of cash and transferred securities, was valued at $1.00 per share
Announced the launch of a company-wide incentive and recognition program, which provides vital new engagement tools and offers new avenues to wealth for all employees across their clinic network
Integrated a new artificial intelligence (AI) platform in partnership with leading software provider Covetrus into the Company’s medical software. The Company believes this is the only AI platform being offered among publicly traded veterinary clinic networks
Acquired 100% ownership interest in one animal hospital located in central Florida (DeBary). The acquisition is expected to add up to approximately $1.8 million in (unaudited) revenue, and brings the Company’s Florida holdings up to 5 clinics
Executive Commentary
“During the second quarter of 2025, we started to see the rewards of our new initiatives, processes, and hard work over the past 18 months with sequential revenue growth of 20% and year over year organic growth of 5.7%.,” said Kimball Carr, Inspire ‘s Chairman, President and Chief Executive Officer. “We also grew our portfolio of clinics to 14 with the recently announced acquisition in Florida while significantly improving our liquidity and capital structure with the recently announced preferred stock transaction. I believe this quarter will mark the turning point for our business model and that our top line growth will accelerate going forward.
Second Quarter 2025 Financial Overview
All comparisons are made relative to the same period in 2024 unless otherwise stated.
For the second quarter of 2025, total revenue was approximately $4.3 million, a decrease of 2% from the prior year period but an increase of 20% from Q1 2025. Comparable clinic revenues increased 5.7% from the prior year period.
Service revenue for the second quarter of 2025 decreased $25,000 or 1%, to $3.2 million. The decrease in service revenue is mainly attributed to the exclusion of KVC from 2025 results and reduced practitioner capacity. These decreases were partially offset by the acquisition of the DeBary animal clinic during Q2 2025.
Product revenue for the second quarter 2025 decreased $82,000, or 7%, to $1.1 million. The overall decrease was a result of customers purchasing less products per visit and the exclusion of KVC from 2025 results partially offset by the acquisition of the DeBary animal clinic during Q2 2025.
Total operating expenses increased $285,000 or 5%. The increase is primarily due to increased costs of consulting agreements relating to customer outreach and public company costs.
Net loss for the first quarter of 2025 decreased $352,000, or 10%, to $3.0 million. The decline in net loss is primarily attributable to the reduction of interest expense and the exclusion of the operating expenses associated with KVC.
Balance Sheet
As of June 30, 2025, the Company had cash and cash equivalents of approximately $0.2 million.
About Inspire Veterinary Partners, Inc.
Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care.
This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding management’s expectations of future financial and operational performance and expected growth and business outlook. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with our limited operating history and history of losses; our ability to continue operating as a going concern; our ability to raise additional capital; our ability to complete additional acquisitions; our ability to recruit and retain skilled veterinarians; our ability to retain existing customers and add new customers; the continued growth of the market in which we operate; our ability to manage our growth effectively over the long-term to maintain our high level of service; the price volatility of our Class A common stock; our ability to continue to have our Class A common stock listed on the Nasdaq Stock Market; the impact of geopolitical conflicts, inflation, and macroeconomic instability on our business, the broader economy, and our ability to forecast our future financial performance; and other risks set forth under the caption “Risk Factors” in our SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Exclusive Letter of Intent for West Coast distribution of Nimbus Boats USA
Expands Nautical Ventures’ lineup with premium Scandinavian‑designed models
Strategic step to broaden Vision Marine’s portfolio after acquiring Nautical Ventures
Enhances choice and experience for boaters in Florida’s top market
FORT LAUDERDALE, FL / ACCESS Newswire / August 14, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”), a leader in premium on‑water experiences and the owner of Florida‑based dealership network Nautical Ventures, today announced that Nautical Ventures has entered into a Letter of Intent with Nimbus Boats USA to exclusively distribute Nimbus powerboats on Florida’s West Coast.
Nimbus’s Tender, Commuter, Weekender and Coupe series are recognized worldwide for their Scandinavian design, versatile layouts and meticulous construction. With more than seventy years of heritage, Nimbus is one of the respected powerboat builders in Europe and North America, and the largest Scandinavian boat builders by volume. Upon entering into definitive agreements, which the parties expect to conclude by March 31, 2026, Nautical Ventures would be authorized to promote, sell and service these models in Florida’s West Coast region beginning August 1, 2025.
“Adding Nimbus to our lineup will be a strategic move to broaden our product portfolio and serve customers who are seeking premium day‑cruiser and weekender boats,” said Alexandre Mongeon, Co‑Founder and Chief Executive Officer of Vision Marine. “Our vision is to curate the best selection of boats on the market and deliver an elevated on‑water experience. This partnership will expand our reach in Florida, leverage the sales and service capabilities of Nautical Ventures and align with our plan to build a diversified portfolio that addresses high‑margin segments. We believe it will position us to capitalize on strong consumer demand and favourable market trends, while continuing to support and grow our existing brand relationships.”
Industry data underpins the commercial rationale for the partnership. Boating and fishing contribute roughly $1.2 trillion to the U.S. outdoor recreation economy and support more than 812,000 jobs [1]. Florida is the largest market for new powerboats, engines and accessories, generating $6.4 billion in sales in 2023, a 3.1 percent increase over the prior year [2]. The National Marine Manufacturers Association projects that new powerboat sales will rebound in 2025, with total boating expenditures expected to rise 3-5 percent above 2024’s record levels [3]. Adventure‑style boats-versatile models designed for day trips, water sports and island hopping-are among the fastest‑growing categories in recreational boating, and Nimbus’s Tender, Commuter, Weekender and Coupe series are squarely in this segment. These trends suggest a sizable and resilient addressable market for high‑quality day boats and weekenders [4].
The Nimbus partnership is one of several initiatives Vision Marine is pursuing as it structures and expands its brand portfolio under new leadership. In June 2025, the Company acquired Nautical Ventures, a Florida‑based recreational boat dealership, marina and service provider widely recognized as one of the top networks in the United States and the number‑one Axopar dealership worldwide. Nautical Ventures operates nine high‑volume retail locations across Florida and distributes a diverse range of premium brands- including Axopar, Beneteau, Brabus, Edgewater, Highfield, NorthStar, Smokercraft, Wellcraft -serving customers from pontoons to luxury yacht owners. The acquisition created North America’s first electric boat propulsion and multi‑brand retail company, combining Vision Marine’s high‑voltage E‑Motion™ powertrain and electric boats with Nautical Ventures’ established sales and service infrastructure. Integrating Nimbus into this platform is part of a broader strategy to offer consumers the best products across propulsion types while supporting long‑term growth for all brands in the Nautical Ventures family.
About Vision Marine
Vision Marine Technologies Inc. (NASDAQ:VMAR) is a leader in high‑performance electric propulsion systems and premium boating experiences. The Company’s proprietary E‑Motion™ 180 horsepower electric outboard is the first high‑voltage system purpose‑built for the marine industry. In June 2025 Vision Marine acquired Nautical Ventures, creating North America’s first electric propulsion and multi‑brand boat retail company. The combined entity operates nine retail locations across Florida and distributes a wide range of prestigious boating brands. By uniting advanced technology with established sales and service infrastructure, Vision Marine aims to accelerate adoption of cleaner, high‑performance boating and provide consumers with an unmatched on‑water experience.
About Nimbus Boats USA
Nimbus Boats USA is the American arm of Nimbus Group, a global leader in the design and manufacture of luxury powerboats. With more than seventy years of heritage, Nimbus has earned a reputation for quality, safety, and innovation, and is the largest Scandinavian boat builder by volume. Its award-winning Tender, Commuter, Weekender, and Coupe series are sold through an extensive international dealer network spanning more than fifty countries. [5].
[5] Nimbus Boats USA information derived from company disclosures and publicly available sources, including Nimbus Group corporate materials.
Forward‑Looking Statement
Certain statements in this press release may constitute “forward‑looking statements” within the meaning of U.S. federal securities laws. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward‑looking statements include, among others, statements regarding the expected terms and timing of the definitive distribution agreement with Nimbus Boats USA, anticipated benefits of the partnership, projected market opportunities and Vision Marine’s strategic outlook. Factors that could affect actual results are detailed in the “Risk Factors” section of Vision Marine’s filings with the U.S. Securities and Exchange Commission. Vision Marine undertakes no obligation to update or revise any forward‑looking statements, except as required by law.
Investor and Company Contact: Bruce Nurse Investor Relations (303) 919‑2913 bn@v‑mti.com
Dr. Gruber provides a guide for surgeon evaluation alongside complication prevention strategies and domestic alternative options which patients should consider.
TAMPA, FLORIDA / ACCESS Newswire / August 14, 2025 / Dr. Meegan Gruber, MD, PhD, who serves as a Board-Certified Plastic Surgeon warns patients to research all safety aspects of surgical tourism prior to scheduling foreign procedures. Each year approximately 150,000 to 320,000 U.S. citizens choose to get medical treatment abroad for cosmetic surgery operations which presents multiple medical and practical and legal dangers to patients when not properly organized.
The appeal of low costs and immediate appointment availability together with eye-catching before-and-after images motivates Dr. Gruber. “But surgery is not a vacation. The choice of surgical location and your operating doctor along with your preoperative and postoperative care management process matters equally to the surgical procedure itself.
Five risks patients often underestimate
Drug-resistant infections. Medical facilities with poor sterilization methods and insufficient oversight have caused difficult to treat infection outbreaks during surgical procedures. The verification process of infection control standards and development of concrete follow-up plans stands as an essential requirement.
Travel + surgery = clot risk. The combination of body contouring surgery with extended periods of travel by flight or car increases the chances of developing DVT/PE. Your surgeon must advise you to spend recovery time in the hospital before traveling home.
Credentials and facilities vary. American Board of Plastic Surgery (ABPS) certification stands as the specialty standard because ABMS recognizes it in the United States. The addition of hospital OR credentialing with AAAHC or QUAD A facility accreditation enhances patient safety standards.
Continuity-of-care gaps. Local physicians face delays in treating complications because they do not have access to your operative records or implant details which results in increased costs.
Limited legal and financial recourse. The different legal systems of various countries create obstacles to resolving problems because each jurisdiction has its own approach to medical malpractice and device monitoring and patient safeguards.
A quick safety checklist from Dr. Gruber
Check if the surgeon holds ABPS certification and matches their name and specialty while asking about their experience performing your target procedure.
Verify that your medical facility holds accreditation from AAAHC or QUAD A or hospital OR status and that emergency procedures are in place.
The anesthesiology details must be confirmed together with information about who will provide the anesthesia. Local anesthesia is suitable for qualified patients but general anesthesia is safer in certain cases and full information about the plan should be provided.
Your recovery period needs to be planned to reduce blood clot risks as well as get medical clearance before departing.
Before your trip you need to arrange follow-up care through defining the number of visits and weekend/night coverage and establishing what will happen during urgent medical situations.
Safer alternatives, without crossing borders
High-quality care performed domestically near patients’ homes provides the safest option when patients need full continuity of medical services before and after surgery. The patients at Gruber Plastic Surgery undergo candidacy screening and receive photography-guided planning and meticulous aftercare services. Local-anesthesia patients maintain continuous communication with their healthcare team during surgical procedures and general anesthesia patients receive detailed preoperative and postoperative monitoring plans. The Out of Town Patient Guide at our practice assists patients who travel within the United States to organize safe medical itineraries with suitable recovery periods and postoperative appointments.
A word from Dr. Gruber
“Prioritize safety over savings. Patients must verify professional credentials while selecting facilities that have received accreditation and they need to allow sufficient time for safe recovery. When you are not sure about something, request a second medical opinion. Our team along with I provide risk-focused consults to help you make well-informed decisions with confidence.” About Gruber Plastic Surgery
Gruber Plastic Surgery, located in Tampa, FL, is led by Dr. Meegan Gruber, Ph.D., board-certified plastic surgeon renowned for her pioneering work in awake plastic surgery. Dr. Gruber, also the star of “Awake Surgery,” which you can stream today on TLC GO, HBO MAX, Hulu, Discovery+, and other streaming platforms, integrates advanced techniques and cutting-edge technology to deliver safe, comfortable, and natural-looking results with minimized recovery time. Specializing in awake surgeries, the clinic offers a range of state-of-the-art procedures. Dr. Gruber is committed to innovation and education, ensuring precision and safety in every treatment, while enhancing patient confidence through individualized care and surgical expertise.
Providing high-fidelity, live mission training capabilities for advanced weapons and tactics training
SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 14, 2025 / Cubic Defense, the world’s leading provider of advanced air combat training, announces the IDIQ contract award by the USAF for activities relating to the procurement, integration, deployment and sustainment of the entire P5 Combat Training Systems (P5CTS) inventory.
“Our P5CTS is designed to provide users with live mission training capabilities for advanced weapons and tactics training,” stated Russ Marsh, President, Cubic Defense. “The system features real-time air-to-air and air-to-ground weapons simulations and live monitoring capabilities. With the recent addition of the P5 Security Subsystem Upgrade (P5 SSU) to enable fully interoperable encrypted Time Space Position Information with Coalition 5th Generation aircraft, Cubic and its partners are continuing to invest and deliver upgrades to the P5 CTS infrastructure to preserve customer investments in authentic training.”
Cubic, along with its principal subcontractor, Leonardo DRS, will be supporting all contractor activities relating to the procurement, integration, deployment, and sustainment. The P5CTS improves U.S. and coalition training used by the USAF, US Marine Corps, US Navy and coalition partners. The system permits the user to continuously relay time, space, position information (TSPI) of the aircraft during training exercises, allowing the warfighter to train as they fight on a common platform with coalition partners.
About Cubic
Cubic creates and delivers technology solutions in transportation that make people’s lives easier by simplifying their daily journeys, and defense capabilities that help promote mission success and safety for those who serve their nation. Led by our talented teams around the world, Cubic is driven to solve global challenges through innovation and service to our customers and partners.
Part of Cubic’s portfolio of businesses, Cubic Defense provides networked Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance and Reconnaissance (C5ISR) products and services and is a leading provider of live, virtual, constructive, and game-based training solutions for both U.S. and Allied Forces. These mission-inspired capabilities enable assured multi-domain access; converged digital intelligence; and superior readiness for defense, intelligence, security and commercial missions. For more information, visit: Cubic Defense.
Recognition serves as a testament to AmeriLife’s unique approach to partnership that helps accelerate growth and innovation for insurance and financial services companies
CLEARWATER, FL / ACCESS Newswire / August 14, 2025 / AmeriLife, a leading provider of financial and insurance solutions, is proud to announce that four of its affiliate partners have been recognized on Inc. 5000’s 2025 list of the fastest-growing private companies in America. This prestigious honor underscores the exceptional growth and innovative spirit of these companies, which are integral to AmeriLife’s mission of empowering individuals to achieve financial security and well-being.
The four partners named to the Inc. 5000 list are:
Florida Financial Advisors– a full-service, comprehensive wealth management and financial planning firm and insurance brokerage dedicated to helping middle-market Americans grow and secure their wealth and achieve their retirement goals.
Brookstone Capital Management– a leading SEC-registered investment Advisory (RIA) firm that offers a robust independent marketing and Turnkey Asset Management Platform (TAMP) to help advisors grow and build scalable, client-first practices.
Pinnacle Financial Services– one of the largest full-service health, life, annuity, and long-term care national marketing organizations, providing financial products and services for individuals, businesses, and their employees.
Florida Financial Advisors, Hoffman Financial Group, and Brookstone Capital Management sit within AmeriLife’s Wealth Group. These firms have consistently demonstrated their ability to provide exceptional financial advice and innovative solutions, helping clients navigate complex financial landscapes and achieve their long-term goals.
“The inclusion of Florida Financial Advisors, Hoffman Financial Group, and Brookstone Capital Management on the Inc. 5000 list is a remarkable achievement,” said Mike Vietri, Chief Distribution Officer for AmeriLife Wealth Group. “These firms have consistently delivered exceptional wealth management services, helping their clients achieve financial security and peace of mind. Their success is a reflection of their commitment to excellence and innovation, and we are honored to have them as part of our wealth distribution channel.”
Pinnacle Financial Services, part of AmeriLife’s Health Distribution, has been recognized for its commitment to delivering high-quality health insurance and financial services, ensuring that clients have the support they need to maintain their health and financial stability.
“We are incredibly proud of Pinnacle Financial Services for being named to the Inc. 5000 list,” said Scotty Elliott, AmeriLife’s Chief Distribution Officer for Health. “Their dedication to providing personalized health and financial solutions has not only driven their success but has also significantly impacted the lives of their clients. This recognition is a testament to their hard work and the value they bring to our community.”
AmeriLife’s Affiliate Partnership Program continues to support its companies’ success, offering a unique and powerful model for modern distribution of health and wealth solutions. The program allows partner firms to maintain their independence post-acquisition while being backed by one of the most sophisticated distribution networks in the nation. By leveraging AmeriLife’s extensive resources, technology, and market expertise, affiliate partners can focus on what they do best-serving their clients-while enjoying the benefits of a robust support system. This strategic alliance not only enhances operational efficiency but also drives significant growth and innovation, as evidenced by the remarkable achievements of these four companies.
The Inc. 5000 list is a highly respected ranking of the nation’s fastest-growing private companies, based on revenue growth over three years. This year’s list represents a diverse range of industries and highlights the resilience and adaptability of America’s entrepreneurial companies. To view all 2025 honorees, visit www.inc.com/inc5000.
About AmeriLife
AmeriLife’s strength lies in its mission: to provide insurance and retirement solutions that help people live longer, healthier lives. AmeriLife develops, markets, and distributes life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For over 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers through a national distribution network of over 300,000 agents, financial professionals, and more than 160 marketing organizations and insurance agencies. For more information, visit AmeriLife.com and follow AmeriLife on Facebook and LinkedIn.
FREDERICKSBURG, VIRGINIA / ACCESS Newswire / August 14, 2025 / In an extraordinary opportunity to change someone’s life through the power of words, the “Write Your Way Home” Contest officially launches on August 15, 2025, giving aspiring homeowners the chance to win a stunning $1.8 million luxury property located at 1200 Prince Edward Street in historic downtown Fredericksburg, Virginia.
The contest challenges entrants to submit a 250- to 500-word essay on the theme: “Why I Want to Live in Historic Downtown Fredericksburg.”
Submissions must be accompanied by a $200 entry fee and received no later than September 29, 2025-45 days after the contest opens.
This modern luxury house is steeped in local charm and architectural beauty and offers the winner a once-in-a-lifetime opportunity to become part of Fredericksburg’s rich cultural legacy.
According to Fredericksburg’s guidebook, the 40-block historic city is full of buildings, each with its own fascinating past. You may explore everything Fredericksburg has to offer by taking a horse-drawn carriage, trolley, or strolling tour. You may enjoy the city’s history and its many restaurants operated by celebrity chefs, art galleries, unique boutiques, and exciting events all year. “This isn’t just a contest to win a house,” said Laurie Webb, Executive Director of the Fredericksburg SPCA. “It’s an opportunity for someone to turn their passion for community, philanthropy, and history into a home-by telling a story that connects heart to place.”
How to Enter:
Write a compelling 250-500 word essay on why you want to live in historic downtown Fredericksburg.
The winning essay will be selected based on originality, emotional impact, and alignment with the contest theme by a panel of independent judges. The probability of winning is 1:15,000-20,000. The contest requires a minimum number of entries. In the event that the contest has more than 15,000 entries, all funds raised above the minimum will be donated to the Fredericksburg Regional Food Bank and the Fredericksburg SPCA.
About Edward & Lewis, LLC
Edward and Lewis, LLC is a privately held real estate development and management company dedicated to delivering quality projects that blend innovation, functionality, and community value. We work to bring together specialized expertise in planning, construction oversight, and property management to ensure a seamless process from concept to completion.
Don’t miss this chance to write your way into a historic home-and a new chapter of your life.
About the Property: Located at 1200 Prince Edward Street, this stately residence blends historic elegance with modern luxury. Nestled in the heart of Fredericksburg’s famed historic district, the home offers 5500 square feet of refined living space, modern luxury, and timeless architectural features.
